Division of Health Care Finance
Landon State Office Building
900 SW Jackson, Suite 900 N
Topeka, Kansas 66612-1220

Kansas
Department of Health and Environment

Phone: 785-296-3981
Fax: 785-296-4813
www.kdheks.gov

Lee A. Norman, M.D., Secretary

Laura Kelly, Governor

Drug Utilization Review Board Meeting
Agenda, Open Session October 14, 2020
10:00 a.m. – 2:00 p.m.

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:
Public/Participant Line: Conf. ID: 9459189 Dial: (833) 713-0101; Passcode: 8675309
WebEx: https://intercall.webex.com/intercall/j.php?MTID=m4c791d74a8a80fbb177d4e108888b89e
Members of the general public are required to complete a conflict of interest form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (October 7, 2020). Please email the completed form to Annette.Grant@ks.gov.

Board Members

Moneeshindra Mittal, MD
James Backes, PharmD
Jennifer Clair, MD
Katie Burenheide Foster, PharmD, MS, BCPS, FCCM
Kristen Powell, PharmD
Serena Stutzman, APRN
Roger Unruh, DO
LaTonyua Rice, PharmD, CGP
Arthur Snow, MD

KDHE-DHCF Staff

Annette Grant, RPh
Victor Nguyen, PharmD

Gainwell Technologies/KEPRO Staff

Karen Kluczykowski, RPh
Kathy Kaesewurm, RN, BSN
Christina Faulkner, PharmD, BCPS
Harry Vu, PharmD

MCO Staff

Alan Carter, PharmD, **Aetna Better Health of Kansas**
Angie Yoo, PharmD, **Sunflower State Health Plan**
Janette Mueller, RPh, **UnitedHealthcare Community Plan**

I. CALL TO ORDER

A. Announcements

This meeting will be operator-assisted. An opportunity for public comment was given at the top of the agenda.

II. OLD BUSINESS

A. Review and Approval of September 10, 2020 Meeting Minutes

III. NEW BUSINESS

A. Revised Prior Authorization (PA) Criteria

1. **Narcolepsy Agents**
   PA criteria were initially approved in January 2020. Since then, Xywav™, a new formulation of oxybate, has been approved. Revised step-therapy criteria are being proposed to ensure appropriate and cost-effective use.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

2. **Monoamine Depletors**
   These criteria were last revised in October of 2017. The PA criteria are being revised to clarify the suicide warnings and use of Austedo® (deutetrabenazine) in certain patients.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

3. **Duchenne Muscular Dystrophy Agents**
   This PA criteria consolidated several drugs into a single class PA and was initially approved in July 2020. Since then, Viltepso™ (viltolarsen) has been approved. Revised criteria are being proposed to ensure appropriate use.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

4. **Acute Migraine Agents**
   These criteria were initially approved in July 2020. They are being presented again to review recommendations made regarding provider type and scoring assessments.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

5. **Chemotherapy Agents**
   These criteria were last reviewed in October 2018. Additional drugs are being proposed for inclusion. Criteria revisions are also being proposed to ensure appropriate use based upon FDA-approved labeling and clinical guidelines.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

6. **Botulinum Toxins**
   These criteria were last reviewed in July 2020. Since then, labeling changes to Botox®, Dysport®, and Xeomin® have occurred. Criteria revisions are being proposed to ensure appropriate use based upon FDA-approved labeling.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

B. New Prior Authorization (PA) Criteria

1. **Neuromyelitis Optica Spectrum Disorder (NMOSD) Agents**
   Multiple medications are now approved for the treatment of NMOSD, including Soliris®, Uplizna™, and Enspryng™. The prior authorization criteria are being proposed to ensure appropriate use based upon the FDA-approved labeling information and clinical guidelines.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

C. Miscellaneous Items

1. **Fee-for-Service Annual Program Assessment**
   The annual program assessment for the Medicaid fee-for-service population will be presented to show drug trends over the past state fiscal year.
   i. Presentation
   ii. Board Discussion

2. **Managed Care Annual Program Assessment**
   Aetna Better Health of Kansas, Sunflower State Health Plan, and UnitedHealthcare Community Plan will present reports detailing utilization trends and provider education efforts for 2019.
   i. Aetna Individual Report – Alan Carter, PharmD
   ii. Sunflower Individual Report – Angie Yoo, PharmD
   iii. UnitedHealthcare Individual Report – Janette Mueller, RPh
   iv. *Public Comment
   v. Board Discussion

IV. OPEN PUBLIC COMMENT

V. ADJOURN

The next DUR Board meeting is scheduled for January 20, 2021.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE****